KRAS and lung carcinoma: Our findings indicate that inhibition of mutant KRAS in lung cancer can phenocopy inhibition of the nuclear export protein exportin 1 (XPO1)10,11, including the effects on EZH2 and DLC1, whereas increased KRAS activity has the opposite effects.